Patients with muscle-invasive bladder cancer who were treated with presurgical chemotherapy may have a 55% lower risk of ...

Given as neoadjuvant treatment, TAR-200 plus cetrelimab generated responses in patients with muscle-invasive bladder cancer.

I present an overview of the management of nonmuscle invasive bladder cancer. The most common intravesical chemotherapeutic agents are described, as well as the impact of chemotherapy on the ...

ImmunityBio's stock has risen sharply this year. Read more on whether investors should look closely at shares or avoid the ...

Investigational TAR-200 monotherapy demonstrates high complete response rate without the need for reinduction or additive therapy in patients who are Bacillus Calmette-Guérin (BCG)-unresponsive1 ...

which is comparing the drug to the investigator's choice of intravesical chemotherapy in patients with high-risk non–muscle-invasive bladder cancer (NMIBC). Interim results reported at last year ...

CG Oncology's bladder cancer molecule, cretostimogene, showed high success with a 75.2% complete response rate in a phase 3 monotherapy study. Cretostimogene, an oncolytic immunotherapy, works by ...

In addition, the phase 3 MoonRISe-1 /BLC3004 (NCT06319820) study is evaluating TAR-210 versus single agent intravesical chemotherapy in participants with intermediate risk non-muscle invasive bladder ...

107822353 NMIBC stage – After the initial TURBT some patients need an immediate intravesical ... bladder cancer – Patients with loco regional disease are offered downstaging chemotherapy ...

A gemcitabine intravesical releasing system ... alone as neoadjuvant therapy in patients with muscle-invasive bladder cancer ...

plus 'intravesical therapy': chemotherapy drugs or TB vaccine BCG applied via catheter. For invasive cancer: radiotherapy or surgery to remove all orpart of bladder. Advanced: intensive chemotherapy.

Definitive treatment of muscle invasive bladder cancer depends on neoadjuvant chemotherapy and surgery ... Dr. Guarionex DeCastro presented the results of a phase II trial of intravesical cabazitaxel, ...